Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079796 | 1.00 | PIK3CA (0.48) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL23927074 | 0.87 | PIK3CA (0.43) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL30079642 | 0.87 | PIK3CA (0.43) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL23927014 | 0.85 | PIK3CD (0.47) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL30079766 | 0.85 | PIK3CD (0.47) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL23927082 | 0.83 | PIK3CA (0.46) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL30079725 | 0.83 | PIK3CA (0.46) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL30079564 | 0.80 | MAPT (0.49) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL23926951 | 0.80 | MAPT (0.49) | PIK3CAPIK3CGPIK3CDPIK3CBKDM4E | |
| SCHEMBL1979739 | 0.79 | KDM4E (0.63) | KDM4EPOLBMEN1ALDH1A1BRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | PIK3CA 2780/4885PIK3CG 2454/4885PIK3CD 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.